Publications
Detailed Information
Improved Gastrointestinal Symptoms and Quality of Life after Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Renal Transplant Patients Receiving Tacrolimus
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hwang, Hyeon Seok | - |
dc.contributor.author | Hyoung, Bok Jin | - |
dc.contributor.author | Kim, Sol | - |
dc.contributor.author | Oh, Ha Young | - |
dc.contributor.author | Kim, Jung Kyung | - |
dc.contributor.author | Kim, Yong Lim | - |
dc.contributor.author | Shin, Gyu Tae | - |
dc.contributor.author | Yang, Chul Woo | - |
dc.contributor.author | Kim, Chan Duck | - |
dc.contributor.author | Kim, Yeong Hoon | - |
dc.contributor.author | Kim, Yon Su | - |
dc.date.accessioned | 2012-06-27T07:30:22Z | - |
dc.date.available | 2012-06-27T07:30:22Z | - |
dc.date.issued | 2010-12 | - |
dc.identifier.citation | JOURNAL OF KOREAN MEDICAL SCIENCE; Vol.25 12; 1759-1765 | ko_KR |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77631 | - |
dc.description.abstract | It is reported that a conversion from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) relieves gastrointestinal (GI) symptom burden and improves health-related quality of life (HRQoL). However, it is unclear whether renal transplant recipients using tacrolimus receive the same benefit from the conversion. In this prospective, multi-center, open-label trial, patients were categorized into two groups by their GI symptom screening. Equimolar EC-MPS (n=175) was prescribed for patients with GI burdens; those with no complaints remained on MMF (n=83). Gastrointestinal Symptom Rating Scale (GSRS) and Gastrointestinal Quality of Life Index (GIQLI) were evaluated at baseline and after one month. Patients and physicians completed Overall Treatment Effect (OTE) at one month. EC-MPS-converted patients had worse GSRS and GIQLI scores at baseline than MMF-continued patients (all P<0.001). Significant improvements in GSRS and GIQLI scores were observed for EC-MPS-converted patients at one month, but MMF-continued patients showed worsened GSRS scores (all P<0.05). OTE scale indicated that EC-MPS patients improved in overall GI symptoms and HRQoL more than MMF patients did (P<0.001). In tacrolimus-treated renal transplant recipients with GI burdens, a conversion from MMF to EC-MPS improves GI-related symptoms and HRQoL. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | KOREAN ACAD MEDICAL SCIENCES | ko_KR |
dc.subject | Mycophenolate mofetil | ko_KR |
dc.subject | Enteric-coated mycophenolate sodium | ko_KR |
dc.subject | Quality of Life | ko_KR |
dc.subject | Gastrointestinal Symptom | ko_KR |
dc.subject | Tacrolimus | ko_KR |
dc.subject | Kidney Transplantation | ko_KR |
dc.title | Improved Gastrointestinal Symptoms and Quality of Life after Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Renal Transplant Patients Receiving Tacrolimus | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 황현석 | - |
dc.contributor.AlternativeAuthor | 형복진 | - |
dc.contributor.AlternativeAuthor | 김솔 | - |
dc.contributor.AlternativeAuthor | 오하영 | - |
dc.contributor.AlternativeAuthor | 김연수 | - |
dc.contributor.AlternativeAuthor | 김정경 | - |
dc.contributor.AlternativeAuthor | 김영훈 | - |
dc.contributor.AlternativeAuthor | 김용임 | - |
dc.contributor.AlternativeAuthor | 김찬덕 | - |
dc.contributor.AlternativeAuthor | 신규태 | - |
dc.contributor.AlternativeAuthor | 양철우 | - |
dc.identifier.doi | 10.3346/jkms.2010.25.12.1759 | - |
dc.citation.journaltitle | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.description.citedreference | Shehata M, 2009, TRANSPL INT, V22, P821, DOI 10.1111/j.1432-2277.2009.00877.x | - |
dc.description.citedreference | Kang NR, 2009, J KOREAN MED SCI, V24, pS129, DOI 10.3346/jkms.2009.24.S1.S129 | - |
dc.description.citedreference | Darji P, 2008, TRANSPL P, V40, P2262, DOI 10.1016/j.transproceed.2008.07.041 | - |
dc.description.citedreference | Bolin P, 2007, TRANSPLANTATION, V84, P1443, DOI 10.1097/01.tp.0000290678.06523.95 | - |
dc.description.citedreference | Cofan F, 2007, TRANSPL P, V39, P2179, DOI 10.1016/j.transproceed.2007.07.012 | - |
dc.description.citedreference | Ekberg H, 2007, TRANSPLANTATION, V83, P282, DOI 10.1097/01.tp.0000251923.14697.f5 | - |
dc.description.citedreference | Bunnapradist S, 2006, TRANSPLANTATION, V82, P102, DOI 10.1097/01.tp.0000225760.09969.lf | - |
dc.description.citedreference | Chan L, 2006, TRANSPLANTATION, V81, P1290, DOI 10.1097/01.tp.0000209411.66790.b3 | - |
dc.description.citedreference | Kaplan B, 2005, CLIN TRANSPLANT, V19, P551, DOI 10.1111/j.1399-0012.2005.00387.x | - |
dc.description.citedreference | Kleinman L, 2005, TRANSPLANT P, V37, P846, DOI 10.1016/j.transproceed.2004.12.106 | - |
dc.description.citedreference | McColl E, 2005, AM J GASTROENTEROL, V100, P11, DOI 10.1111/j.1572-0241.2005.40945.x | - |
dc.description.citedreference | Fallone CA, 2004, ALIMENT PHARM THERAP, V20, P1161, DOI 10.1111/j.1365-2036.2004.02257.x | - |
dc.description.citedreference | Salvadori M, 2004, AM J TRANSPLANT, V4, P231, DOI 10.1046/j.1600-6143.2003.00337.x | - |
dc.description.citedreference | Budde K, 2004, AM J TRANSPLANT, V4, P237, DOI 10.1046/j.1600-6143.2003.00321.x | - |
dc.description.citedreference | Meier-Kriesche HU, 2003, AM J TRANSPLANT, V3, P68 | - |
dc.description.citedreference | Behrend M, 2001, DRUG SAFETY, V24, P645 | - |
dc.description.citedreference | Filler G, 2000, PEDIATR NEPHROL, V14, P100 | - |
dc.description.citedreference | Zucker K, 1997, TRANSPL IMMUNOL, V5, P225 | - |
dc.description.citedreference | Pirsch JD, 1997, TRANSPLANTATION, V63, P977 | - |
dc.description.citedreference | Keown P, 1996, TRANSPLANTATION, V61, P1029 | - |
dc.description.citedreference | JONES RH, 1995, EUR J GEN PRACT, V1, P149 | - |
dc.description.tc | 1 | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.